AI Drug Discovery Hits Legal Wall Over Human Inventorship Requirements

The rapid acceleration of AI-driven drug discovery is colliding with a rigid legal framework that refuses to recognize non-human inventors. This tension has created a precarious gap for biotech firms that market their breakthroughs as AI-generated while filing patents that credit only humans.

Insilico Medicine recently highlighted this discrepancy with its TNIK inhibitor (INS018_055), a drug candidate for pulmonary fibrosis. The company utilized its Pharma.AI platform to move the drug from target discovery to a preclinical candidate in just 18 months. Despite claiming the platform "discovered" the drug, the corresponding patent filing named five humans—including CEO Alex Zhavoronkov—as the inventors. This maneuver reflects a necessity of the current legal landscape: US courts have ruled that AI cannot be an inventor because the law defines an inventor as an "individual," which specifically means a human being.

The Legacy of Patent Law

Drug discovery has traditionally been a slow, human-led endeavor. Modern firms are now deploying generative AI platforms, such as Biology42 and Chemistry42, to identify biological targets and design molecular structures at speeds previously impossible. These tools can propose chemical structures that human researchers might overlook, effectively performing the cognitive act of invention. However, intellectual property statutes were written long before the advent of generative AI, leaving a conflict between the technical reality of how these drugs are found and the legal requirements for securing a patent.

The Risk to Innovation

This legal bottleneck creates a strategic dilemma for the pharmaceutical industry. If AI-generated outputs are excluded from patent protection because they lack a human inventor, the financial incentive to invest in AI-driven development could vanish. Patents provide the exclusivity necessary to recoup the massive costs of clinical trials.

Conversely, listing humans as inventors for work primarily performed by an algorithm opens the door to litigation. If it is proven in court that no human contributed enough intellectual effort to qualify as an inventor, the patents could be invalidated. Sarah Korman, Chief Business Officer and Legal Officer of Isomorphic Labs, emphasized the stakes, stating, "There needs to be a human inventor or there’s no invention and no patent."

The Path Forward

For now, companies are attempting to bridge the gap by framing AI as a sophisticated tool rather than a creator. Alex Zhavoronkov argues that human agency remains central to the process, noting that even in a fully roboticized system, "someone will still push the button and give the budget."

Industry observers are now watching whether the US Patent and Trademark Office or the courts will evolve their definitions of "individual" to accommodate machine learning. Until then, the biotech sector remains in a fragile position, balancing the marketing of AI's autonomy with the legal requirement of human authorship.